Oct 28 2009
POZEN Inc. (NASDAQ: POZN), today announced results for the third quarter ended September 30, 2009.
Third Quarter Results
POZEN reported a net income of $6.7 million, or $0.22 per share on a diluted basis, for the third quarter of 2009, compared to net loss of $(7.9) million, or $(0.26) per share on a diluted basis, for the third quarter of 2008.
For the third quarter of 2009, POZEN reported revenue of $14.3 million resulting from a $10 million milestone payment for the New Drug Application (NDA) filing for VIMOVO™ (naproxen/esomeprazole magnesium), the amortization of upfront payments received pursuant to the collaboration agreement with AstraZeneca of $3.1 million and royalties of $1.2 million on sales of Treximet® (sumatriptan and naproxen sodium). Revenue for the third quarter ended September 30, 2008 totaled $11.1 million, resulting from the amortization of upfront payments received pursuant to the collaboration agreements with AstraZeneca and GlaxoSmithKline of $3.2 million, $7.5 million of revenue for development work, and $0.4 million of royalties on sales of Treximet.
Operating expenses for the third quarter of 2009 totaled $7.7 million as compared to $19.5 million for the comparable period in 2008. The decrease in operating expenses was primarily due to a decrease in costs associated with the PN 400 development program.
At September 30, 2009, cash, cash equivalents and short-term investments totaled $51.3 million compared to $61.7 million at December 31, 2008. The Company continues to anticipate ending the year with greater than $45.0 million in cash and investments.
Nine-Month Results
POZEN reported a net loss of $(1.1) million, or $(0.04) per share on a diluted basis, for the nine month period ended September 30, 2009, compared to a net loss of $(1.9) million, or $(0.06) per share on a diluted basis, for the same period in 2008.
For the nine months ended September 30, 2009, POZEN reported revenue of $28.0 million compared to $52.1 million for the same period in 2008. The decrease in revenue was primarily due to $14.6 million less development revenue in 2009 and $10.0 million less in milestone payments in 2009.
Operating expenses for the nine months ended September 30, 2009 were $29.5 million as compared to $55.7 million for the same period in 2008. The decrease in operating expenses was primarily due to a decrease in costs for the PN 400 development program.
Source POZEN